# Study of Enteric-Coated Mycophenolate Sodium (EC-MPS) Plus Reduced-dose Cyclosporine Microemulsion (CsA-ME) Compared to EC-MPS Plus Standard Dose CsA-ME in Eldery de Novo Renal Transplant Recipients Treated With Basiliximab and Short-term Steroids

> **NCT00239031** · PHASE3 · COMPLETED · sponsor: **Novartis** · enrollment: 117 (actual)

## Conditions studied

- Denovo Renal Transplantation

## Interventions

- **DRUG:** Enteric-Coated Mycophenolate Sodium

## Key facts

- **NCT ID:** NCT00239031
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-03
- **Primary completion:** 2005-07
- **Final completion:** 2005-07
- **Target enrollment:** 117 (ACTUAL)
- **Last updated:** 2011-01-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00239031

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00239031, "Study of Enteric-Coated Mycophenolate Sodium (EC-MPS) Plus Reduced-dose Cyclosporine Microemulsion (CsA-ME) Compared to EC-MPS Plus Standard Dose CsA-ME in Eldery de Novo Renal Transplant Recipients Treated With Basiliximab and Short-term Steroids". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT00239031. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*